You are correct. CEO hinted at it. Was of course mocked by the usual detractors who are not paying enough attention to changes going on the FDA. DFU is of course a pressing issue in the US with far too many amputations for a first world country:
"Diabetes is the leading risk factor for lower-extremity amputation in U.S. adults, with an estimated 150,000 diabetes-related major or minor amputations per year. Lifetime risk of any lower-extremity amputation among people with DFU is at least 19%"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797649/#:~:text=Diabetes%20is%20the%20leading%20risk,least%2019%25%20(56).
150,000!!! That's massive. Nearly 1 in 2,000 US people get amputations a year from Diabetes in the US, which is obviously rife. I think an accelerated approval on a phase II trial with a possible phase III confirmatory trial as a condition, a very real possibility.
- Forums
- ASX - By Stock
- CYP
- Ann: DFU Clinical Trial Enrolment Complete
CYP
cynata therapeutics limited
Add to My Watchlist
5.41%
!
17.5¢

Ann: DFU Clinical Trial Enrolment Complete, page-11
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
17.5¢ |
Change
-0.010(5.41%) |
Mkt cap ! $41.80M |
Open | High | Low | Value | Volume |
17.5¢ | 17.5¢ | 17.5¢ | $85 | 485 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12515 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.5¢ | 212973 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12515 | 0.175 |
4 | 99347 | 0.170 |
7 | 215420 | 0.165 |
5 | 177563 | 0.160 |
6 | 234436 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.185 | 212973 | 1 |
0.190 | 20217 | 1 |
0.195 | 174646 | 3 |
0.200 | 55400 | 2 |
0.210 | 20000 | 1 |
Last trade - 11.01am 13/08/2025 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |